Kymera Therapeutics (KYMR) Investor Presentation - Slideshow

• Large opportunity in wide variety of cancers MDM2 CRISPR Sensitivity Score Graph generated with data obtained from DepMap.org 0.6 0.4 0.2 0 -0.2 -0.4 -0.6 -0.8 -1 -1.2 -1.4 -1.6 -1.8 -2 -2.2 p53MUT p53WT Cell Line p53 Degrader Inhibitor p53 ub ub ub MDM2 MDM2 p53 Degradation p53 Targets p53 Feedback Loop Tumor Suppression Apoptosis (Noxa, Bax, Puma) DNA Damage Hypoxia Oncogenes Other • MDM2 small molecule inhibitors of MDM2/p53 interaction show activity in the clinic.. Degrader Advantage • MDM2 degrader c ...